|

Mosunetuzumab Clinical Trials

25 actively recruiting trials across 16 locations

▲ +1 trial since May 2026

Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A +7 more

Pipeline

Phase 1: 4Phase 2: 14Phase 3: 2Phase 1/2: 4

Top Sponsors

  • University of Washington2
  • National Cancer Institute (NCI)2
  • M.D. Anderson Cancer Center2
  • Hoffmann-La Roche2
  • City of Hope Medical Center2

Indications

  • Cancer24
  • B Cell Lymphoma4
  • High-grade B-cell Lymphoma3
  • Diffuse Large B-Cell Lymphoma3
  • Follicular Lymphoma3

Other4 trials

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Phase 2
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Phase 2
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

Duarte, California3 trials

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

City of Hope Medical Center

Phase 2
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Comprehensive Cancer Center

Phase 1

Phoenix, Arizona2 trials

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Mayo Clinic in Arizona - Phoenix

Phase 1/2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Houston, Texas2 trials

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

MD Anderson Cancer Center

Phase 2
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M D Anderson Cancer Center

Phase 2

Seattle, Washington2 trials

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama1 trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

University of Alabama at Birmingham Cancer Center

Phase 3

Tucson, Arizona1 trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Clovis, California1 trial

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

University of California San Francisco - Fresno Center for Medical Education and Research

Phase 1

New Haven, Connecticut1 trial

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Yale Cancer Center

Phase 2

Washington D.C., District of Columbia1 trial

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Georgetown University (Data Collection Only)

Phase 2

Miami, Florida1 trial

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

University of Miami

Phase 2

Boston, Massachusetts1 trial

Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital

Phase 1/2

Rochester, Minnesota1 trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Mayo Clinic Rochester

Phase 1

St Louis, Missouri1 trial

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Washington University School of Medicine

Phase 1

Omaha, Nebraska1 trial

CAR-T Followed by Bispecific Antibodies

University of Nebraska Medical Center

Phase 2

Rochester, New York1 trial

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Wilmot Cancer Institute

Phase 2

Portland, Oregon1 trial

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

OHSU Knight Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.